[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-368398-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-368398-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","177-lu-lnc1004-radioligand-therapy-in-patients-with-end-stage-metastatic-cancers-a-single-center-single-arm-phase-ii-study","177 Lu-LNC1004 Radioligand Therapy in Patients with End-stage Metastatic Cancers - A Single-Center, Single-Arm, Phase II Study","","Purpose: Fibroblast activation protein (FAP) is highly expressed in cancer-associated fibroblasts and some tumor cells, making it a promising target. This phase II study assessed the efficacy and safety of 177Lu-Evans blue–FAP inhibitor (177Lu-LNC1004) radioligand therapy (RLT) for end-stage metastatic tumors. Patients and Methods: Single-arm, single-center trial enrolled 28 progressive patients with high FAP expression after exhausting approved options. Results: Disease control occurred in 46% of patients, associated with improved PFS and OS. Conclusions: 177Lu-LNC1004 RLT was well tolerated with an acceptable toxicity profile and promising outcomes.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/177-lu-lnc1004-radioligand-therapy-in-patients-with-end-stage-metastatic-cancers-a-single-center-single-arm-phase-ii-study/368398/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/177-lu-lnc1004-radioligand-therapy-in-patients-with-end-stage-metastatic-cancers-a-single-center-single-arm-phase-ii-study/368398.png","ImageObject",300,407,{"name":42,"@type":43},"Margaret","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-06","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the primary objective of this phase II radioligand therapy study?","Question",{"text":63,"@type":64},"To evaluate the efficacy of 177Lu-LNC1004 by using post-RLT radiologic response as the primary endpoint.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were patients selected for high FAP expression?",{"text":68,"@type":64},"Patients had progressive metastatic malignancies with high FAP expression, defined as a maximum standardized uptake value ≥10 in more than 50% of tumors.",{"name":70,"@type":61,"acceptedAnswer":71},"What safety findings were reported for treatment-related toxicities?",{"text":72,"@type":64},"Grade 3/4 hematotoxicity occurred in 21% of patients, with thrombocytopenia, leukopenia, and neutropenia most common; no grade 3/4 hepatotoxicity or nephrotoxicity was observed.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},368398,1790198903,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":112,"preview_page_count":33,"preview_urls":145},137451207643,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","177 Lu-LNC1004 Radioligand Therapy in Patients with End-stage Metastatic Cancers: A Single-Center, Single-Arm, Phase II Study  \nHao Fu1, Jingxiong Huang1, Liang Zhao1, Yuhang Chen2, Weizhi Xu1, Jiayu Cai1, Lingyu Yu1, Yizhen Pang1,3,4, Wei Guo1, Bishan Su1, Long Sun1, Hua Wu1, Jingjing Zhang4,5,6,7, Xiaoyuan Chen4,5,6,7,8,9,10,11, and Haojun Chen1  \n|  |  | A |  | B | S |  | T | R |  | A |  | C | T |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n|  | Purpose: Fibroblast activation protein (FAP) is highly expressed in cancer-associated fibroblasts and certain tumor cells, making it a promising therapeutic target for various malignancies. This study evaluated the efficacy and safety of 177Lu-Evans blue–FAP inhibitor (177Lu-LNC1004) radioligand therapy (RLT) for treating end-stage metastatic tumors.\u003Cbr>Patients and Methods: This single-arm, single-center, phase II trial included 28 patients with progressive metastatic malignancies (11 types) and high FAP expression (defined as a maximum standardized uptake value ≥10 in >50% of tumors) who had exhausted all approved therapies, screened between June 2022 and April 2024. Patients were scheduled to receive four 177Lu-LNC1004 RLT cycles at 3.33 GBq/cycle every 6 weeks. The primary endpoint was post-RLT radiologic response. The secondary endpoints were progression-free survival (PFS), overall survival (OS), dosimetry, and safety.\u003Cbr>􀀶 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | Results: Eastern Cooperative Oncology Group scores >2 were observed in 68% of patients. Overall, 63 177Lu-LNC1004 RLT cycles were performed, with 19 (68%) patients undergoing ≥2 cycles. Disease control was achieved in 13 (13/28, 46%) patients, with 4 and 9 patients demonstrating partial response and stable disease, respectively, and associated with improved PFS and OS (P \u003C 0.001). The mean absorbed dose in tumors was 4.69 ± 3.83 Gy/GBq (1.18– 25.03 Gy/GBq). Treatment-related grade 3/4 hematotoxicity was observed in six (21%) patients, with thrombocytopenia, leukopenia, and neutropenia most prevalent. No grade 3/4 hepatotoxicity ornephrotoxicity was observed.\u003Cbr>Conclusions: FAP-directed RLT using 177Lu-LNC1004 at 3.33 GBq/cycle was well tolerated with an acceptable toxicity profile. Nearly half of patients achieved disease control, which was associated with prolonged PFS and OS. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n\nIntroduction  \nCancer-associated fibroblasts (CAF) are the most prevalent stromal cells in the tumor microenvironment (TME) and constitute a substantial portion of the cellular composition of tumor tissues (1) . Fibroblast activation protein (FAP), a member of the dipeptidylpeptidase protein family, is highly expressed on CAFs across >90% of epithelial tumors (2, 3) . FAP-expressing CAFs promote tumor development and metastasis by influencing extracellular matrix remodeling, intracellular signaling, angiogenesis, epithelial-to-  \n1Department of Nuclear Medicine and Minnan PET Center, Xiamen K","cbCaic02lRmSW5Ma","https://ap.wps.com/l/cbCaic02lRmSW5Ma","pdf",21349494,12,"English","# Purpose\n# Patients and Methods\n# Results\n# Conclusions\n# Introduction\n## Target biology: FAP and CAFs\n## Rationale: therapy resistance in metastatic cancer","[{\"question\":\"What was the primary objective of this phase II radioligand therapy study?\",\"answer\":\"To evaluate the efficacy of 177Lu-LNC1004 by using post-RLT radiologic response as the primary endpoint.\"},{\"question\":\"How were patients selected for high FAP expression?\",\"answer\":\"Patients had progressive metastatic malignancies with high FAP expression, defined as a maximum standardized uptake value ≥10 in more than 50% of tumors.\"},{\"question\":\"What safety findings were reported for treatment-related toxicities?\",\"answer\":\"Grade 3/4 hematotoxicity occurred in 21% of patients, with thrombocytopenia, leukopenia, and neutropenia most common; no grade 3/4 hepatotoxicity or nephrotoxicity was observed.\"}]","177 Lu-LNC1004 Radioligand Therapy in Patients with End-stage Metastatic Cancers - A Single-Center, Single-Arm, Phase II Study | PDF",1790176752,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/361d58b02d58450fd61f733be8b629f9.webp",983,1315,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2bdf964cf98e6fd9b0fb89f987c2ea9f.webp",982,1314,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/571e918ff691c78a76baa6908217772e.webp",981,1312,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/00ad29c7a53b3501106331f3d068a7d4.webp",980,1311]